Pfizer’s Zithromax (azithromycin)
Executive Summary
NDA filed for the short course, once-daily, oral antibiotic product, Pfizer announced April 26. Pfizer is seeking approval for use in treating upper and lower respiratory tract infections; skin and skin structure infections; chlamydia and pediatric infections.